Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study (NCT02947945) | Clinical Trial Compass
RecruitingPhase 2
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
United States10 participantsStarted 2017-09-12
Plain-language summary
Reslizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5. The study medicine, reslizumab, is not yet approved for doctors to treat patients with EGPA. It is considered an experimental drug in this study.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Informed Consent: Able to give written informed consent prior to participation in the study, which will include the ability to comply with the requirements and restrictions listed in the consent form. Subjects must be able to read, comprehend, and write at a level sufficient to complete study related materials.
* Gender and Age: Male or female subjects \>18 years old
* EGPA diagnosis: subjects who have been diagnosed with EGPA for at least 6 months based on the history or presence of: asthma plus eosinophilia (\>1.0x109/L and/or \>10% of leucocytes) plus at least two of the following additional features of EGPA:
* A biopsy showing histopathological evidence of eosinophilic vasculitis, or perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation;
* Neuropathy, mono or poly (motor deficit or nerve conduction abnormality);
* Pulmonary infiltrates, non-fixed;
* Sino-nasal abnormality;
* Cardiomyopathy (established by echocardiography or MRI);
* Glomerulonephritis (haematuria, red cell casts, proteinuria);
* Alveolar haemorrhage (by bronchoalveolar lavage);
* Palpable purpura;
* ANCA positive (MPO or PR3).
* Subjects who have received a cyclophosphamide (CYC) induction regimen may be included a minimum of 2 weeks after the last dose of daily oral CYC, or 3 weeks after the last dose of pulsed IV CYC prior to visit 1, if their total WBC is ≥4x109/L prior to visit 1.
* Subjects who have received a methotrexate, aza…
What they're measuring
1
Document the safety of reslizumab therapy in patients with EGPA